Main Sequence, Australia's leading deep tech venture firm, has promoted Dr. Elaine Stead from Principal to Partner. The appointment comes as the firm strengthens its leadership team ahead of its fourth fund, with a first close targeted for the end of the year. Stead has played a central role in shaping the firm's healthcare investment strategy since joining in March 2024.
Leadership Expansion Ahead of Fund 4
The promotion reflects Main Sequence's broader effort to build a deep leadership bench before launching Fund 4. The firm has already seen two portfolio companies, Gilmour Space Technologies and Advanced Navigation, reach unicorn status over the past year. This momentum is supported by the growth of Atmosphere, the firm's Pre-Seed program backing Australian scientists at the earliest stage.
A Year of Milestones
CSIRO recently quadrupled its commitment to Atmosphere, bringing the total to A$20 million. This expanded support highlights the growing confidence in Main Sequence's approach to commercializing scientific research. The firm is now actively in market for its fourth fund, with a first close planned before the end of the year.
Healthcare Portfolio Under Stead's Leadership
Stead has been instrumental in driving the firm's healthcare thesis across a diverse portfolio of companies. Her work spans Kinoxis Therapeutics, Currus Biologics, Macrobiome Therapeutics, Xylo, and Xoma Labs. These companies are developing therapies for substance use disorders, solid tumors, inflammatory bowel disease, neuropsychiatric conditions, and non-invasive continuous glucose monitoring.
A Career Built on Science and Company Building
Stead brings a rare combination of scientific and entrepreneurial experience to her new role. She holds a PhD in Biochemistry with a focus on Stem Cell Biology and first-class honors in Biochemistry, Microbiology, and Immunology. After founding her own company, she spent more than a decade in venture capital before joining Main Sequence.
Executive Perspectives on the Promotion
Managing Partner Bill Bartee said, "Great returns come from staying ahead of where the science is going, which means always having the right expertise in the room." He added that Stead reflects this principle in healthcare and that her promotion reflects the caliber of team being built for Fund 4. Bartee emphasized the firm's commitment to real depth in every area it backs.
Outlook for Australian Innovation
Stead said Australia has one of the world's strongest track records for health and medical innovation. She pointed to the country's repeated production of transformative science and its world class clinical research environment as key advantages. Stead added that she looks forward to bringing that same conviction to Fund 4.
Commitment to Patient Capital and Diverse Backers
Stead emphasized that her motivation comes from watching patience pay off in both the science and the company builders who commit to it. She said she is focused on ensuring that people backing Australian science are as diverse as the research itself. Her own path from lab bench to boardroom gives her a vantage point few investors hold.
Stead's promotion signals Main Sequence's intent to deepen its healthcare expertise while preparing for its next investment cycle. The firm is pairing a proven leadership team with a growing pipeline of Australian scientific ventures at stages from Pre-Seed to later company building. With Fund 4 on the horizon, Main Sequence is positioning itself to back the next generation of deep tech breakthroughs.